More Russian investment coming, AIPM says; FDA warning cut antipsychotic use, study shows;

 @FiercePharma:  GSK settles more Avandia litigation for $250M. Report | Follow @FiercePharma

> More global drugmakers will soon announce plans to establish a local presence in Russia in response to government measures to boost its domestic sector and cut dependence on imports, industry group AIPM said. Report

> An official warning about newer antipsychotics in demented elderly people appears to have deterred some doctors from prescribing the drugs, a new U.S. study shows. News

> GlaxoSmithKline is moving its 1,300 employees in downtown Philadelphia to a high-tech new building at the city's former Navy Yard. Item

> "Black box" drug warnings prompted by FDA safety reviews are not always consistent from drug to drug within a particular class, a new study suggests. Article

> In a status report on FDA's DDMAC policy-making, Director Tom Abrams said a process for implementing a 2007 law requiring drug firms to pre-submit some TV ads will be forthcoming this year. Report

> Novartis' generics unit Sandoz is working on eight to 10 new biosimilar molecules to cement its position as leading maker of copycat versions of pricey biotech drugs, the unit's head told Handelsblatt. Story

> Galderma Pharma said the conditions for the completion of its takeover offer for Q-Med AB haven't been fulfilled. News

Biotech News

@FierceBiotech: Can small enterprises replace a Pfizer? News |  Follow @FierceBiotech

@JohnCFierce: Andrew Pollack at the NYT gives RNAi the treatment. From irrational exuberance to irrational pessimism. Item |   Follow @JohnCFierce 

> Why the long wait for a final Genzyme deal? Story

> Novo hatches blockbuster plans for "me-slightly better" insulin. Item 

> Sandoz lunges for the lead in the pricey biosimilar race. Article 

> Investors ready to craft new biotechs out of Pfizer's discards. Report 

> A.P. Pharma scrambling to cut more costs, scout new financing. Item

Drug Delivery News

> MicroCHIPS begins testing implantable osteoporosis pump. Item

> Echo Therapeutics: Prelude delivery device launch on track. Article

> Real-time MRI-guided drug delivery demonstrated. Story

> Nanoparticles with loose grips get drugs to tumors fast. Report

> A little story about attractive drug-delivering particles. Item

Medical Device News

> Roche glucose monitors removed from NY Medicaid program. News 

> Elenza garners $24M for implantable ocular lens. Report

> BD to buy Accuri for undisclosed sum. Article

> FDA proposal seeks to speed device approval. Story 

> FDA OKs Medtronic's MRI-friendly pacemaker. Item  

And Finally... Winter hurts: Across the battered Northeastern U.S., doctors report a spike in strained muscles from shoveling snow, broken bones from slick stairs and sidewalks, and dangerously low blood banks as fewer people venture out. Report

Suggested Articles

Seattle Genetics and Astellas’ newcomer Padcev now has what every cancer drugmaker is looking for: Randomized trial data showing it can extend lives.

A patent decision in Delaware clears the way for multiple generic companies to launch their Tecfidera copycats—and target its $3.3B in U.S. sales.

Sanofi and GlaxoSmithKline signed a deal with the EU to supply up to 300 million doses of their recombinant protein-based COVID-19 vaccine.